Oral propranolol is successful in treating periocular infantile haemangiomas.

Article

A study published in the Archives of Ophthalmology has confirmed the safety and efficacy of oral propranolol for the treatment of periocular infantile haemangiomas.

A study published in the Archives of Ophthalmology has confirmed the safety and efficacy of oral propranolol for the treatment of periocular infantile haemangiomas.

Dr Tara G. Missoi et al., Department of Ophthalmology, University of Missouri–Columbia, Missouri, USA, treated periocular hemangiomas from 17 children with oral propranolol 3 times a day. To document haemangioma, size serial examinations and external photography were used. The starting dose was 0.5mg for 1 week, then 1mg for 1 week and 2mg for the remainder of treatment.

Findings demonstrated that propranolol reduced the size of all infantile haemangiomas. Astigmatism was lowered by 33%, surface area reduced by 39% and vision was equalized in all but 1 child. The mean change in surface area was 61% of the original size. In 2 patients there was some rebound growth that did not require retreatment. Amblyopia was found in 7 patients and 1 patient experienced a benign episode of bradycardia.

Early use of propranolol is effective in treating and improving visual acuity in periocular infantile hemangiomas.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.